Evaluation of the effect of tranilast on rats with spinal cord injury

Mitsuru Hanada, Koji Tsutsumi, Hideyuki Arima, Ryuichi Shinjo, Yuki Sugiura, Shiro Imagama, Naoki Ishiguro, Yukihiro Matsuyama

研究成果: Article

7 引用 (Scopus)

抄録

Results Motor function recovery, BBB score, and the %grip test were significantly higher in the tranilast-treated groups than in the control group. At week 1 after SCI, inflammatory-cell invasion was more severe and Iba1 expression was significantly higher in the control group. At week 8, although the number of GFAP-positive cells increased greatly from the impaction site to the proximal and distal sites in the control group, these cells were confined around a cavity in the tranilast-treated groups. GFAP distribution coincided with that of fibronectin. Anti-CS antibody level in the tranilast-treated groups was significantly lower than that in the control group.

Conclusions Tranilast inhibits inflammation in the acute phase of SCI and reduces glial and fibrotic scars and could present a new method for treating SCI.

Background Glial and fibrotic scars inhibit neural regeneration after spinal cord injury (SCI). N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor β, alleviates allergic reactions, and decreases hypertrophic skin scars. We evaluated its ability to improve motor function and inhibit the spread of tissue damage in rats with SCI.

Methods Rats with SCI were divided into groups that received tranilast (30 mg/[kg·day]) by intravenous administration (group IV), tranilast (200 mg/[kg·day]) by oral administration (group OR), and saline injections (control). Motor functions were assessed by determining Basso, Beattie, and Bresnahan (BBB) scores and %grip tests for 8 weeks after SCI. Histological evaluation of ionized calcium binding adaptor molecule 1 (Iba1) at 1 week after SCI and glial fibrillary acidic protein (GFAP), fibronectin, and chondroitin sulfate (CS) at week 8 was performed.

元の言語English
ページ(範囲)209-215
ページ数7
ジャーナルJournal of the Neurological Sciences
346
発行部数1-2
DOI
出版物ステータスPublished - 2014 11 15

Fingerprint

Spinal Cord Injuries
Glial Fibrillary Acidic Protein
Control Groups
Chondroitin Sulfates
Hand Strength
Fibronectins
Neuroglia
Cicatrix
Calcium
Hypertrophic Cicatrix
tranilast
Recovery of Function
Transforming Growth Factors
Intravenous Administration
Oral Administration
Regeneration
Hypersensitivity
Inflammation
Skin
Injections

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

これを引用

Hanada, M., Tsutsumi, K., Arima, H., Shinjo, R., Sugiura, Y., Imagama, S., ... Matsuyama, Y. (2014). Evaluation of the effect of tranilast on rats with spinal cord injury. Journal of the Neurological Sciences, 346(1-2), 209-215. https://doi.org/10.1016/j.jns.2014.08.028

Evaluation of the effect of tranilast on rats with spinal cord injury. / Hanada, Mitsuru; Tsutsumi, Koji; Arima, Hideyuki; Shinjo, Ryuichi; Sugiura, Yuki; Imagama, Shiro; Ishiguro, Naoki; Matsuyama, Yukihiro.

:: Journal of the Neurological Sciences, 巻 346, 番号 1-2, 15.11.2014, p. 209-215.

研究成果: Article

Hanada, M, Tsutsumi, K, Arima, H, Shinjo, R, Sugiura, Y, Imagama, S, Ishiguro, N & Matsuyama, Y 2014, 'Evaluation of the effect of tranilast on rats with spinal cord injury', Journal of the Neurological Sciences, 巻. 346, 番号 1-2, pp. 209-215. https://doi.org/10.1016/j.jns.2014.08.028
Hanada, Mitsuru ; Tsutsumi, Koji ; Arima, Hideyuki ; Shinjo, Ryuichi ; Sugiura, Yuki ; Imagama, Shiro ; Ishiguro, Naoki ; Matsuyama, Yukihiro. / Evaluation of the effect of tranilast on rats with spinal cord injury. :: Journal of the Neurological Sciences. 2014 ; 巻 346, 番号 1-2. pp. 209-215.
@article{0934b469b7ac48b69687888c23e769c4,
title = "Evaluation of the effect of tranilast on rats with spinal cord injury",
abstract = "Results Motor function recovery, BBB score, and the {\%}grip test were significantly higher in the tranilast-treated groups than in the control group. At week 1 after SCI, inflammatory-cell invasion was more severe and Iba1 expression was significantly higher in the control group. At week 8, although the number of GFAP-positive cells increased greatly from the impaction site to the proximal and distal sites in the control group, these cells were confined around a cavity in the tranilast-treated groups. GFAP distribution coincided with that of fibronectin. Anti-CS antibody level in the tranilast-treated groups was significantly lower than that in the control group.Conclusions Tranilast inhibits inflammation in the acute phase of SCI and reduces glial and fibrotic scars and could present a new method for treating SCI.Background Glial and fibrotic scars inhibit neural regeneration after spinal cord injury (SCI). N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor β, alleviates allergic reactions, and decreases hypertrophic skin scars. We evaluated its ability to improve motor function and inhibit the spread of tissue damage in rats with SCI.Methods Rats with SCI were divided into groups that received tranilast (30 mg/[kg·day]) by intravenous administration (group IV), tranilast (200 mg/[kg·day]) by oral administration (group OR), and saline injections (control). Motor functions were assessed by determining Basso, Beattie, and Bresnahan (BBB) scores and {\%}grip tests for 8 weeks after SCI. Histological evaluation of ionized calcium binding adaptor molecule 1 (Iba1) at 1 week after SCI and glial fibrillary acidic protein (GFAP), fibronectin, and chondroitin sulfate (CS) at week 8 was performed.",
keywords = "Fibrotic scar, Glial scar, Inflammation, Motor function, Spinal cord injury, Tranilast",
author = "Mitsuru Hanada and Koji Tsutsumi and Hideyuki Arima and Ryuichi Shinjo and Yuki Sugiura and Shiro Imagama and Naoki Ishiguro and Yukihiro Matsuyama",
year = "2014",
month = "11",
day = "15",
doi = "10.1016/j.jns.2014.08.028",
language = "English",
volume = "346",
pages = "209--215",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Evaluation of the effect of tranilast on rats with spinal cord injury

AU - Hanada, Mitsuru

AU - Tsutsumi, Koji

AU - Arima, Hideyuki

AU - Shinjo, Ryuichi

AU - Sugiura, Yuki

AU - Imagama, Shiro

AU - Ishiguro, Naoki

AU - Matsuyama, Yukihiro

PY - 2014/11/15

Y1 - 2014/11/15

N2 - Results Motor function recovery, BBB score, and the %grip test were significantly higher in the tranilast-treated groups than in the control group. At week 1 after SCI, inflammatory-cell invasion was more severe and Iba1 expression was significantly higher in the control group. At week 8, although the number of GFAP-positive cells increased greatly from the impaction site to the proximal and distal sites in the control group, these cells were confined around a cavity in the tranilast-treated groups. GFAP distribution coincided with that of fibronectin. Anti-CS antibody level in the tranilast-treated groups was significantly lower than that in the control group.Conclusions Tranilast inhibits inflammation in the acute phase of SCI and reduces glial and fibrotic scars and could present a new method for treating SCI.Background Glial and fibrotic scars inhibit neural regeneration after spinal cord injury (SCI). N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor β, alleviates allergic reactions, and decreases hypertrophic skin scars. We evaluated its ability to improve motor function and inhibit the spread of tissue damage in rats with SCI.Methods Rats with SCI were divided into groups that received tranilast (30 mg/[kg·day]) by intravenous administration (group IV), tranilast (200 mg/[kg·day]) by oral administration (group OR), and saline injections (control). Motor functions were assessed by determining Basso, Beattie, and Bresnahan (BBB) scores and %grip tests for 8 weeks after SCI. Histological evaluation of ionized calcium binding adaptor molecule 1 (Iba1) at 1 week after SCI and glial fibrillary acidic protein (GFAP), fibronectin, and chondroitin sulfate (CS) at week 8 was performed.

AB - Results Motor function recovery, BBB score, and the %grip test were significantly higher in the tranilast-treated groups than in the control group. At week 1 after SCI, inflammatory-cell invasion was more severe and Iba1 expression was significantly higher in the control group. At week 8, although the number of GFAP-positive cells increased greatly from the impaction site to the proximal and distal sites in the control group, these cells were confined around a cavity in the tranilast-treated groups. GFAP distribution coincided with that of fibronectin. Anti-CS antibody level in the tranilast-treated groups was significantly lower than that in the control group.Conclusions Tranilast inhibits inflammation in the acute phase of SCI and reduces glial and fibrotic scars and could present a new method for treating SCI.Background Glial and fibrotic scars inhibit neural regeneration after spinal cord injury (SCI). N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor β, alleviates allergic reactions, and decreases hypertrophic skin scars. We evaluated its ability to improve motor function and inhibit the spread of tissue damage in rats with SCI.Methods Rats with SCI were divided into groups that received tranilast (30 mg/[kg·day]) by intravenous administration (group IV), tranilast (200 mg/[kg·day]) by oral administration (group OR), and saline injections (control). Motor functions were assessed by determining Basso, Beattie, and Bresnahan (BBB) scores and %grip tests for 8 weeks after SCI. Histological evaluation of ionized calcium binding adaptor molecule 1 (Iba1) at 1 week after SCI and glial fibrillary acidic protein (GFAP), fibronectin, and chondroitin sulfate (CS) at week 8 was performed.

KW - Fibrotic scar

KW - Glial scar

KW - Inflammation

KW - Motor function

KW - Spinal cord injury

KW - Tranilast

UR - http://www.scopus.com/inward/record.url?scp=84910145667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910145667&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2014.08.028

DO - 10.1016/j.jns.2014.08.028

M3 - Article

C2 - 25194634

AN - SCOPUS:84910145667

VL - 346

SP - 209

EP - 215

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -